Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DPDW is not dependent on near shore drilling that certain parties are clamoring for. In fact, if that type of drilling continues to be banned, it can only help the deep water servicers, IMHO.
-Fred
Tom, that 30% rig count reduction is in shallow water jack-up rigs in GOM where DPDW has little if any presence.
Good luck!
-Fritz
$7.00 Target? They're really going out on a limb! What brass balls they have! LOL!
-Fritz
Dzielak read this whole article (it is in several parts.)
It will save you money and heartache.
http://www.babypips.com/school/leverage_the_killer.html
Good luck!
-Fritz
LOL!
Thanks, it's good practice to include a link so your readers can go back to the source for complete context.
Good luck!
-Fritz
What is your source for this?
Thanks
-Fritz
Halozyme Therapeutics Names New Chief Financial Officer
-- Kurt Gustafson to become CFO effective May 15 --
SAN DIEGO--(BUSINESS WIRE)--Apr. 13, 2009-- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology, and drug delivery markets, today announced the appointment of Kurt Gustafson as Vice President, Finance. Mr. Gustafson will assume the role of Chief Financial Officer on May 15. David Ramsay, Halozyme’s current CFO, will transition to the new position of Vice President, Corporate Development.
“We are delighted to welcome an individual with Kurt’s industry experience, stature and expertise as an integral new member of our executive leadership team at Halozyme,” said Jonathan Lim, M.D., President and CEO. “Kurt’s knowledge and experience will be of tremendous value as we enter the next phase of our growth. This transition of senior management exemplifies one of our core values, which is to recruit, develop and retain exceptional talent and to provide new opportunities and foster professional growth within our organization.”
Mr. Gustafson brings to Halozyme’s senior management team a unique combination of operational and managerial experience in financial planning and analysis, accounting, treasury, and international responsibility gained during his 18 years with Amgen. In his most recent position, as Vice President, Manufacturing Finance, Mr.Gustafson was responsible for financial planning and cost accounting for each of Amgen’s worldwide manufacturing sites and the Cost Accounting Group. Some of his previous positions at Amgen include: Vice President, Finance and CFO of Amgen Europe with responsibility for financial planning and accounting for European operations from 2004-2006, head of corporate financial planning and analysis from 2000-2004, and treasurer from 1998-2000. Before joining Amgen, he was with the accounting firm Laventhol & Horwath in Chicago. He received his BS in accounting from North Park University in Chicago and an MBA from UCLA.
David Ramsay joined Halozyme as Chief Financial Officer in 2003. His numerous achievements and accomplishments at Halozyme include spearheading the process of taking Halozyme public in 2004, closing multiple rounds of financing to help the company raise over $180 million, including equity investments made by Roche and Baxter, supporting the Roche and Baxter collaborations, negotiating and signing the Baxter HYLENEX collaboration, establishing and developing the company’s accounting, financial, and IT infrastructure, and implementing Sarbanes-Oxley compliance rules.
“I am thrilled that David will be leading corporate development efforts at Halozyme, and greatly appreciate his many years of outstanding service as CFO,” said Jonathan Lim. “Halozyme would not be where it is today without David’s commitment to excellence, unwavering dedication, and significant accomplishments. I will continue to rely on his counsel and guidance and eagerly look forward to working with him in his new role.”
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme’s Enhanze™ Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche to apply Enhanze Technology to Roche’s biological therapeutics for up to 13 targets and with Baxter BioScience to apply Enhanze Technology to Baxter’s biological therapeutic compound, GAMMAGARD LIQUID. Halozyme’s research pipeline candidates target significant areas of unmet medical need. For more information visit www.halozyme.com.
Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the CFO transition plan) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.
Source: Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc.
Robert H. Uhl
Senior Director, Investor Relations
858-704-8264
ruhl@halozyme.com
http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=irol-newsArticle&ID=1275756&highlight=
As are their press releases. LOL!
-Fritz
Y/W, Kermit! I honestly feel that the Babypips article on leverage combined with Silvani's book have put me in a position to take advantage of the opportunities in the forex market.
Good luck!
-Fritz
LOL! I'd be comfortably retired in a week!
In Silvani's book he shows two charts from two diffrent feeds and clearly demonstrates that they are different.
-Fritz
There is nothing illegal about this and that's one reason why it is so rampant. The forex market is virtually unregulated. Your broker is able to see your stops and can go for them in an instant. Secondly, your broker is providing you your data feed. They can make it go anywhere they want. LOL! As I said, they are the only party you are trading with. It's a myth that you are trading on an open market. There is no open exchange on forex. You are not buying from nor selling to other individuals as you would on a stock exchange. Your broker absorbs your trades and then in turn deals them to his counter parties which may be the very large banks or other dealers or even other traders like yourself. Your broker makes money two ways: via the spread from your trading and dealing on his own account. It is in the context of dealing on his own account that he gets motivated to go stop hunting. Just imagine: the E/U is trading around 1.3150 among the large institutions but he sees your S/L at 1.3130. It's a snap for him to drop the price for a few seconds to pick up your "offer" at 1.3130 and go back to his counter parties and sell them at 1.3150. Free money and perfectly legal.
-Fritz
Yes, at first hearing it strikes one as a goofy conspiracy to newbies (like me LOL!) who are used to stock trading on an open exchange. But with forex you are not trading on an exchange. Your broker is the only counterparty you are trading with. In fact, FXCM to their credit places a warning in their website stating that they are trading against you. To be perfectly honest, I didn't understand this and simply dismissed it until I read Silvani's book. Then the warning jumped out at me like a giant red tomato being thrown at my head. LOL!
As someone mentioned here today, a large part of the problem is the over use of leverage places us in an untenable dilemma: i.e., tight stops and get taken out repeatedly vs. looser stops and risk a huge loss if the market goes against you. Either way you lose and eventually margin calls take their inevitable toll.
In this regard, the second eye opening article I recommend to all is the one entitled "The Number One Cause of Death for Forex Traders"
http://www.babypips.com/school/leverage_the_killer.html
This article at BabyPips.com helped me to complete my education on all the mistakes I've been making in Forex.
If you don't over use margin and keep to the recommended ratio as found in the Babypips article, you can place very loose stops while not risking huge losses. At the same time you can leave a trade on for a while and wait for the trend to catch up with your analysis while ignoring the market noise and stop hunters. This week was a perfect example for me as I shorted the E/U at the first of the week but there were large swings
throughout the week which would have taken me out if I was over-leveraged. As it was I simply waited it out and got to take my profits yesterday as I knew I would.
IMHO, these two resources are absolutely fundamental for any aspiring Forex trader. Failure to understand the concepts in Silvani's book and the Babypips article will guaranty blowing up one's account over and over again. I'm speaking from hard experience and I wish I'd learned these things some thousands of dollars ago. But, then again I've always learned things the hard way LOL!
Good luck!
Fritz
You are not imagining this. The broker that you use is trading against you and will take out your stops every time they find it to their advantage, which will be most of the time LOL!. They know exactly where your stops are and will gun for them routinely. This is the dirty little secret of Forex trading.
I lost some serious cash to them (I use FXCM but they are all doing this) until I got a clue.
If you find that you are correctly gauging the trend of the particular cross you are trading and place your stops in a well thought out strategy, then see your stops taken out only to see the market then go back to your original trendline, I strongly suggest reading "Beat the Forex Dealer" by Augustin Silvani before you place another trade. This book is absolutely invaluable and will make you a better trader. (You don't have to believe me - check out the reviews on Amazon!)
Good luck!
-Fritz
I gave up on them because their news releases were never followed up with any concrete progress.
I still keep an eye on them to see if they can actually build something other than a press release.
Good luck!
-Fritz
Halofan:
First, I'm clearly no expert in T/A either and have always been open about that.
Second, I do agree that the low $6.00 range is a short term resistance point. The key to your observation, IMHO, is the phrase "in the last several months". A look at a longer term chart shows a little more historical perspective, such as the one I include below. After we clear the $6.41 resistance point there is no major hurdle until 2 dollars later at the low $8.00.
Looking at the chart below, since December we are in a bullish up trend. We tested the low sixes in January and pulled back in a classic retracement of about 50%. We are now in another ascending channel beginning at the retracement low of $3.93 and are now challenging resistance once again starting in early March. Nothing goes straight up and this is a very healthy chart, IMHO. The money flow indicators are positive, indicating buying interest outweighs the sellers.
Profit taking at certain levels is inevitable and that's a large part of the pull backs. Another reason, that I've mentioned before, is the macro environment in which we find ourselves. Buy and hold is out of favor and you hear a constant refrain that we are in a "trader's market". This causes some instability as well since the "strong hands" that typically stabilize a particular stock have been beaten senseless by the events of the last 9 months. If the overall market finds some degree of secure footing then that will inevitably help HALO crash through resistance points because there will be fewer sellers offering their shares for short term profit taking.
Thirdly, I also agree with you that fundamentals are primary and, in fact, are the true driver in any investment. In that regard, I believe we are in a very good position.
In the mean time let's bounce off of that middle bollinger band and aim for $6.50 by the end of the month.
Good luck!
-Fritz
Today's chart contains a good example of a bullish engulfing candle (see ibox). My technical analysis musings have been laughable in recent months but I've always felt that these charts
are useful only in normal environments and far less so in Crazy Town such as we have found ourselves in since last fall. So with that caveat I mention the bullish formation with great trepidation, but if the G-20 meetings don't make Wall Street and other investors suicidal this week then we may see a very nice move from HALO in April. Going back to some of my T/A comments in the past month or two, I was predicting a strong move up to the high single digits with an assault on 10 not out of the question. These thoughts were belied by, IMHO, macro economic events which essentially had nothing to do with HALO but in the end had everything to do with the progress of the stock price. If the S&P500 maintains a firm footing then I reiterate my earlier prognostications.
Good luck!
-Fritz
Lilly and HALO?
Interesting article from Wall Street Journal.
This is just a snippet as I don't have a subscription.
Lilly wants to look to buy smaller fry rather than participate in a mega merger.
Rod, haven't you suggested in the recent past that Lilly might be
interested in HALO?
-Fritz
----------------------------------------------------------
http://blogs.wsj.com/health/2009/03/30/lilly-ceo-not-interested-in-merger-with-bristol-myers-squibb/
* March 30, 2009, 9:26 AM ET
By Sarah Rubenstein
Eli Lilly is resisting getting caught up in the wave of drug-industry consolidation.
After Pfizer-Wyeth, Merck/Schering-Plough and Roche-Genentech, Lilly CEO John Lechleiter told the Financial Times his company isn’t interested in a mega-merger, and he ruled out a tie-up with Bristol-Myers Squibb.
“I think we are seeing deals that are really driven more by weakness than what I would describe as strong strategic combinations,” Lechleiter told the FT. “That will improve short-term problems but fail to answer the long-term question of research productivity.”
As the WSJ explained a few weeks ago, Lilly is looking relatively small in the wake of the mega mergers, and it’s facing the loss of patent protection of the big-selling antipsychotic Zyprexa in 2011. Lilly would more likely be a buyer than a seller. Still, a spokesman told the WSJ that the company isn’t interested in large-scale M&A and believes that “small and medium scale acquisitions, licensing and internal development” are the best way forward for Lilly.
“Call me a stubborn Midwesterner, but I/we continue to believe that these megadeals never made any sense to begin with and don’t make sense now,” Lechleiter wrote in an in-house blog post, as quoted by the FT. “We are flat out not interested in being part of a big combination.”
Update: Lechleiter tells the WSJ he is interested in acquisitions of up to about $15 billion. “I got hungry again about three weeks after ImClone got closed,” he said.
diabetes drugs face U.S. grilling
http://www.reuters.com/article/marketsNews/idINLQ94146520090326?rpc=44&sp=true
Thu Mar 26, 2009 8:37am EDT
* Onglyza reviewed by FDA panel April 1, Victoza April 2
* Focus on cardiovascular safety of both diabetes drugs
* Share prices may be volatile
By Ben Hirschler
LONDON, March 26 (Reuters) - Two new diabetes drugs face tough appraisals from U.S. experts next week, promising a volatile ride for shares in Novo Nordisk (NOVOb.CO: Quote, Profile, Research, Stock Buzz), AstraZeneca (AZN.L: Quote, Profile, Research, Stock Buzz) and Bristol-Myers Squibb (BMY.N: Quote, Profile, Research, Stock Buzz).
Investors are nervous about prospects for Novo's Victoza, or liraglutide, and AstraZeneca and Bristol's Onglyza, or saxagliptin, both of which could face safety issues that delay their approval in the key U.S. market.
Worries have been heightened since March 6, when Takeda Pharmaceutical (4502.T: Quote, Profile, Research, Stock Buzz) said the U.S. Food and Drug Administration (FDA) needed more data to review its new diabetes drug alogliptin, sending the Japanese group's stock tumbling.
Onglyza, which will be assessed by the FDA's Endocrinologic and Metabolic Drugs Advisory Committee on April 1, belongs to the same DPP-4 drug class as alogliptin.
The only successful DPP-4 drug at present is Merck & Co's (MRK.N: Quote, Profile, Research, Stock Buzz) Januvia, which had sales of $1.4 billion in 2007. Novartis (NOVN.VX: Quote, Profile, Research, Stock Buzz) was also an early pioneer of DPP-4s but it has struggled to get rival medicine Galvus to market.
If successful, Onglyza could theoretically generate sales of more than $3 billion a year, some analysts believe. But most are forecasting just $200 million to $400 million, reflecting uncertainties about its chances in front of a cautious FDA.
Underlining that caution, the FDA in December told companies with diabetes drugs in early-stage development it wanted more evidence on cardiovascular risk, following a scare over heart risks with GlaxoSmithKline's (GSK.L: Quote, Profile, Research, Stock Buzz) Avandia.
Doubts have also grown about Novo's Victoza, which will go in front of the same committee on April 2.
The Danish company is confident its drug has an excellent cardiovascular safety profile and says it has not been asked by the FDA to conduct any more clinical studies before approval.
But many investors still fear a delay is possible.
Confidence in Victoza -- the key driver for Novo in the years ahead -- has weakened in recent months because of worries about the FDA's stance and slowing sales of Amylin Pharmaceuticals' (AMLN.O: Quote, Profile, Research, Stock Buzz) rival product Byetta.
Both Victoza and Byetta belong to the GLP-1 class of injectable drugs that stimulate insulin release only when glucose levels become too high.
Consensus forecasts for Victoza have come down to around $1.3 billion to $1.5 billion, according to analysts at Citigroup, nearer the brokerage's own cautious prediction of $1.2 billion in 2015. (Editing by Sharon Lindores)
© Thomson Reuters 2008. All rights reserved. Users may download and print extracts of content from this website for their own personal and non-commercial use only. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters and its logo are registered trademarks or trademarks of the Thomson Reuters group of companies around the world.
Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
Idaho, interesting point. Do you know generally what area of research this article may be focused on?
-Fritz
Phu, IMHO, it's just macro market forces at play and not something specific to HALO. Money has found it's appetite for risk again and capital is moving back into equities in general. As an example, the British and US sale of government debt was rather undersubscribed both yesterday and today. Remember when folks would buy the stuff regardless of the interest rate offered just to park cash in a safe place? Those days are evidently behind us - at least today anyway. LOL.
Good luck!
-Fritz
brwtrpilot: thanks for the report.
It was the most compelling reading by a brown water pilot since Sam Clemens himself!
Good luck!
-Fritz
With the 10K filed and the P/P issue in the rear-view mirror, the quiet period is certainly over.
We should be treated to a steady stream of news going forward.
A couple of contract announcements should put most people to rights.
Good luck!
-Fritz
Euro Forecast Unclear on Euro Zone Fears, Financial Conditions
031309_forecast_eur
Euro Forecast Unclear on Euro Zone Fears, Financial Conditions
Fundamental Outlook for Euro This Week: Bearish
- Euro gains slow on weak retail sales data
- Improved investor sentiment nonetheless improves euro outlook
- Euro nears a technical breakout
The euro finished at multi-week highs against the US Dollar, as a week-long rally in the S&P 500 hurt the safe-haven US currency. The short-term correlation between the EUR/USD and the S&P remains near record-highs, and recent trends imply that further stock market gains would lead to Euro strength. Wave after wave of bearish European economic data nonetheless limits optimism for the heavily-traded EMU currency. Fresh economic distress highlights structural risks to the Euro Zone, and FX markets will keep a close eye on developments through the weekend’s G20 summit.
Traders await the conclusions from contentious meetings likely to take place among global economic leaders. US officials have clearly stated their desire for an aggressive global response to the economic and financial crises, but their European counterparts have shown clear resistance to matching sizeable US fiscal and monetary stimuli. Fears of snowballing fiscal deficits and the terms of EU membership prohibit many members from aggressive public spending, and this may in fact leave the Euro Zone at a disadvantage. Furthermore, the European Central Bank seemingly lacks the power to enact similarly aggressive monetary policy. These two key limitations suggest that the US may enjoy more favorable conditions for eventual economic recovery. The risks of EMU and ECB inaction on domestic financial and economic crises continue to mount, and the euro could potentially suffer against the US dollar through the medium term as a result.
Through the shorter-term, traders will keep a close eye out for the coming week’s key European inflation and investor confidence results. Analysts predict that Euro Zone Consumer Price Index inflation picked up through the month of February. Such results could further handicap the European Central Bank’s ability to boost domestic economic prospects. Unless we see real risks of deflation, the ECB is unlikely to drop interest rates far beyond current levels. Otherwise, surprises in upcoming German ZEW figures could elicit responses in financial markets and—by extension—the euro itself. Given that the EUR/USD continues to trade almost tick-for-tick with global stock indices, it will be critical to watch whether the S&P 500’s recent recovery leads to further short-term gains.
Euro Outlook
21:11 GMT March 13th EUR/USD opened New York around 1.2895, was bid up to
1.2930 on early US equity market strength, then sold off to 1.2885 on news that
the US trade deficit narrowed more than expected, down to $36bn on a drop in
exports of 5.7% being outweighed by imports falling 6.7% as the recession grips
harder. The pair rebounded as stocks jumped again, hit 1.2937, then slipped away
as equities dipped into the red, and EUR/JPY sold off, the pair hit 1.2860,
bottomed, and ground higher as equities regained their composure. The rest of
the session was a steady grind higher, with the close at 1.2925, S&P +0.77%.
News from the summit from EU leaders has been uncommonly sparse so far,
perhaps indicative of little common ground as the US and Japan want more
stimulus, whilst Germany and France baulk. ECB"s Wellink "it may take Iceland a
generation to solve its problems"; "No option for Greece or any other country to
leave EMU": "Bank capital requirements should be raised". ECB"s Stark sees
"further losses in financial sector"; "Effects of European fiscal stimulus will
not be felt until end "09, into 2010". All eyes on the final statement.
Peter.Wadkins@ThomsonReuters.com
You called that one weeks ago, Rod.
Good luck!
-Fritz
Halozyme to Present at Investor Conference and Scientific Meeting
SAN DIEGO--(BUSINESS WIRE)--Mar. 11, 2009-- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology, and drug delivery markets, today announced that David A. Ramsay, Halozyme’s CFO, will present at the Cowen and Company 29th Annual Healthcare Conference on Wednesday, March 18, 2009 at 8:00 a.m. EDT (5:00 a.m. PDT) at the Marriott Copley Place in Boston.
Interested parties can access a live audio webcast and accompanying slides of the company presentation via the Internet by visiting the Investor Relations section of Halozyme’s Web site at www.halozyme.com. An archived presentation will be available on the Halozyme Web site for 30 days following the presentation date.
Halozyme will also be presenting three posters with preclinical scientific data for PEGPH20 at the American Association of Cancer Research (AACR) Annual Meeting in Denver on April 19. Previous studies in mouse tumor models that produce hyaluronan have demonstrated that PEGPH20 removed HA from the tumor microenvironment and reduced tumor interstitial fluid pressure resulting in tumor growth inhibition and prolonged time to progression.
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme’s Enhanze™ Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche to apply Enhanze Technology to Roche’s biological therapeutics for up to 13 targets and with Baxter BioScience to apply Enhanze Technology to Baxter’s biological therapeutic compound, GAMMAGARD LIQUID. Halozyme’s research pipeline candidates target significant areas of unmet medical need. For more information visit www.halozyme.com.
Source: Halozyme Therapeutics, Inc.
Halozyme
Robert H. Uhl
Senior Director, Investor Relations
858-704-8264
ruhl@halozyme.com
http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=irol-newsArticle&ID=1265116&highlight=
Nettles, thanks a million!
Good luck!
-Fritz
Nettles, how do you get the news feed working on FXCM? I can't find the correct button! LOL!
Thanks and good luck!
-Fritz
I believe that this is very significant news.
-Fritz
---------------------------------------------------------------
The ICE Recieves The Go Ahead From The SEC To Clear Credit Default Swaps
The Intercontinental Exchange (ICE) cleared its last hurddle to begin clearing credit default swaps today after the Securities and Exchange Commission granted the firm an exemption. This was last regulatory hurddle for the ICE after winning approval for aquiring Clearing Corp. (owned by the largest CDS dealers) from the Justice Department and Federal Trade Commission and then receiving permission to clear from the governing Federal Reserve Board. This will provide a sense of confidence for an otherwise frozen, $27 trillion derivative market. Previously, these swaps were traded over the counter with no guarantee on counterparty risk. A clearing house acts as a counterparty to both buyer and seller. Should this revive liquidity, it will remove one of the greatest threats for another financial crisis.
http://www.dailyfx.com/story/market_alerts/fundamental_alert/The_ICE_Recieves_The_Go_1236394227829.html
One thing is certain, DPDW's not going to zero like GM.
-Fritz
Halozyme Therapeutics to Host Conference Call and Webcast on March 13 to Discuss 2008 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Mar. 6, 2009-- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology, and drug delivery markets, today announced that it plans to report its fourth quarter and full year 2008 financial results on Friday, March 13, 2009 before the open of the financial markets. The announcement will be followed by a conference call with the investment community at 8:00 a.m. PST, (11:00 a.m. EST) which will be simultaneously broadcast over the Internet. Management will discuss the financial results and highlights for the fourth quarter and full year 2008 and provide a product pipeline update.
To participate by telephone please dial 888-256-9044 for domestic callers or 706-643-5585 for international callers and provide the conference ID # 88158522. Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of the company’s web site at www.halozyme.com. Shortly after the call an audio replay will be available on Halozyme’s web site for 30 days. A telephone replay will be available by dialing 800-642-1687 from the U.S., or 706-645-9291 for international callers.
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme’s Enhanze™ Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche to apply Enhanze Technology to Roche’s biological therapeutic compounds for up to 13 targets and with Baxter BioScience to apply Enhanze Technology to Baxter’s biological therapeutic compound, GAMMAGARD LIQUID™. The product candidates in Halozyme’s research pipeline target multiple areas of significant unmet medical need. For more information visit www.halozyme.com.
Source: Halozyme Therapeutics, Inc.
Halozyme Contact
Robert H. Uhl, Senior Director, Investor Relations
858-704-8264
ruhl@halozyme.com
http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=irol-newsArticle&ID=1263443&highlight=
Excellent!, Thanks! eom
-Fritz
strongtower, I'm using FXCM Micro acct and I don't see an option for live news feeds. But, that's exactly what I'm liooking for. Maybe I'll have to wait til I graduate to their (or someone else's) full account.
Regards,
-Fritz
Thanks for the heads up, Simplegreen!
-Good luck!
-Fritz
Question re: news source.
Hi, folks. Was wondering what you use as your the preferred source of forex related news?
Thanks
Good luck!
-Fritz
git, thanks for sharing that. It's a new and valuable addition to my tool kit!
Good luck!
-Fritz
Thanks, for the welcome! Good luck to all!
-Fritz
EUR/USD: Since the gap down yesterday it has touched all three Fib retracement levels. With that out of the way I believe we start out for new lows. (Warning: I'm pretty new at this so we'll see....)
Good luck!
-Fritz